Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To assess the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy. PATIENTS AND METHODS: The s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dahut, William L., Madan, Ravi A., Karakunnel, Joyson J., Adelberg, David, Gulley, James L., Turkbey, Ismail B., Chau, Cindy H., Spencer, Shawn D., Mulquin, Marcia, Wright, John, Parnes, Howard L., Steinberg, Seth M., Choyke, Peter L., Figg, William D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660464/
https://ncbi.nlm.nih.gov/pubmed/23419134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2012.11667.x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi